William T Regenold1, Robert J Noorani2, Deborah Piez3, Palak Patel3. 1. Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: wregenol@psych.umaryland.edu. 2. Department of Anesthesiology, University of Maryland School of Medicine, Baltimore, MD, USA. 3. Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
Abstract
BACKGROUND: Electroconvulsive therapy (ECT) is the most effective therapy for treatment resistant major depressive disorder (TRD); however, some individuals with TRD refuse ECT over concern about adverse cognitive effects. Clinical observation of two patients with TRD who had a therapeutic response to intended ECT despite having only one or no seizure suggested that nonconvulsive electrical stimulation may be effective in some patients. OBJECTIVE/HYPOTHESIS: This study tested the hypothesis that electrical brain stimulation applied like standard ECT, but below seizure threshold, can have therapeutic effects on TRD with fewer adverse cognitive effects. METHODS: Thirteen outpatients with TRD (6 unipolar, 7 bipolar) who refused ECT participated in this open label adjunctive treatment study of nonconvulsive electrotherapy (NET) at the University of Maryland Medical Center. Brief pulse bifrontal electrical stimulation was given thrice weekly with a Thymatron System IV Integrated ECT Instrument. RESULTS: Seizure-free data were obtained from 11 of 13 subjects. Group mean Hamilton Depression Rating Scale 17-item version scores declined significantly (P = 0.001) from 20.3 to 8.6. Response and remission rates were 73% (8) and 55% (6), respectively. Cognitive testing using the Mini-Mental State Exam and the Autobiographical Memory Inventory-Short Form did not show declines typically observed with ECT. CONCLUSIONS: The therapeutic effect of NET on TRD was similar to that of ECT. Serious adverse effects and adverse cognitive effects were not observed. These results challenge the widespread belief that a seizure is necessary for the antidepressant effect of ECT and merit further investigation to determine whether NET is a viable alternative to ECT in some patients with TRD. Clinical trial posted on www.clinicaltrials.gov, identifier: NCT01065597.
BACKGROUND: Electroconvulsive therapy (ECT) is the most effective therapy for treatment resistant major depressive disorder (TRD); however, some individuals with TRD refuse ECT over concern about adverse cognitive effects. Clinical observation of two patients with TRD who had a therapeutic response to intended ECT despite having only one or no seizure suggested that nonconvulsive electrical stimulation may be effective in some patients. OBJECTIVE/HYPOTHESIS: This study tested the hypothesis that electrical brain stimulation applied like standard ECT, but below seizure threshold, can have therapeutic effects on TRD with fewer adverse cognitive effects. METHODS: Thirteen outpatients with TRD (6 unipolar, 7 bipolar) who refused ECT participated in this open label adjunctive treatment study of nonconvulsive electrotherapy (NET) at the University of Maryland Medical Center. Brief pulse bifrontal electrical stimulation was given thrice weekly with a Thymatron System IV Integrated ECT Instrument. RESULTS:Seizure-free data were obtained from 11 of 13 subjects. Group mean Hamilton Depression Rating Scale 17-item version scores declined significantly (P = 0.001) from 20.3 to 8.6. Response and remission rates were 73% (8) and 55% (6), respectively. Cognitive testing using the Mini-Mental State Exam and the Autobiographical Memory Inventory-Short Form did not show declines typically observed with ECT. CONCLUSIONS: The therapeutic effect of NET on TRD was similar to that of ECT. Serious adverse effects and adverse cognitive effects were not observed. These results challenge the widespread belief that a seizure is necessary for the antidepressant effect of ECT and merit further investigation to determine whether NET is a viable alternative to ECT in some patients with TRD. Clinical trial posted on www.clinicaltrials.gov, identifier: NCT01065597.
Authors: Miklos Argyelan; Leif Oltedal; Zhi-De Deng; Benjamin Wade; Marom Bikson; Andrea Joanlanne; Sohag Sanghani; Hauke Bartsch; Marta Cano; Anders M Dale; Udo Dannlowski; Annemiek Dols; Verena Enneking; Randall Espinoza; Ute Kessler; Katherine L Narr; Ketil J Oedegaard; Mardien L Oudega; Ronny Redlich; Max L Stek; Akihiro Takamiya; Louise Emsell; Filip Bouckaert; Pascal Sienaert; Jesus Pujol; Indira Tendolkar; Philip van Eijndhoven; Georgios Petrides; Anil K Malhotra; Christopher Abbott Journal: Elife Date: 2019-10-23 Impact factor: 8.140
Authors: Konstantinos N Fountoulakis; Lakshmi N Yatham; Heinz Grunze; Eduard Vieta; Allan H Young; Pierre Blier; Mauricio Tohen; Siegfried Kasper; Hans Jurgen Moeller Journal: Int J Neuropsychopharmacol Date: 2020-04-23 Impact factor: 5.176
Authors: Jennifer Hopp; Autusa Pahlavan; Mary Richert; Kathryn Grimes; Kate Turlington; Maureen Cassady; Mark D Kvarta; Scott M Thompson Journal: Front Psychiatry Date: 2022-07-22 Impact factor: 5.435